Bibliographical noteFunding Information:
Haematological Malignancy Diagnostic Centre, Viapath at King’s College Hospital, London SE5 9RS, UK; aaDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032; bbDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115; ccCancer Immunology and Cancer Epidemiology Programs, Dana-Farber Harvard Cancer Center, Boston, MA 02115; and ddBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142 Competing interest statement: C.L.S. is employed through Torreyana Corp, San Diego, CA; Blackhawk Genomics, Concord, CA; and Advagenix, Rockville, MD. Volunteer activities of C.L.S. include those for College of American Pathologists, Northfield, IL, and Clinical Laboratory Standards Institute, Wayne, PA. T.J.O. is a Member, Scientific Advisory Committee, MioDx and Integrated Nano-Technologies. A.W.I.L.’s laboratory receives sponsorships from AstraZeneca (HK) Ltd. and MSD (HK) Ltd. for providing selected companion diagnostic tests free to public patients. N.C. is an employee at Quest Diagnostics, Inc. F.A.M. is an employee and stock option holder at Castle Biosciences, Inc. A.B.C. is paid teaching faculty for the American Medical Informatics Association Clinical Informatics Board Review Course and receives small honoraria as well as travel reimbursement to speak at multiple scientific and professional medical society meetings. T.L.P. has been consulted (compensated) for Bio-Rad, Inc. and is Director of Pathology Strategies for the Sturge Weber Foundation (compensated). H.E.W. has employment through Viapath, a majority National Health Service-owned independent pathology service provider; has been a paid faculty member at Kingston University, accepted paid accommodation and subsistence as an invited speaker to Cytocell User Group meeting for the United Kingdom and Ireland, and accepted paid event registration as an invited speaker to Digital Pathology/Global Engage meeting. H.E.W.’s laboratory received scholarship funds from The International Council for Standardization in Haematology for providing JAK2 testing. The other authors (K.F., E.A.B., P.M., N.R.P., K.P.P., B.S., M.S., M.L.G., S.M.M., H.F., and S.O.) do not have any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this article.
This work was supported in part by grants from the US National Institutes of Health (U24 HG003345 to E.A.B., R35 CA197735 to S.O., R01 CA151993 to S.O., R21 CA230873 to S.O., R01 CA248857 to S.O.) and from the Wellcome Trust UK (208349/Z/ 17/Z to E.A.B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.